ASP Isotopes' Renergen to Begin Helium Production; Nasdaq Listing Planned
ASP Isotopes Inc. issued a shareholder letter detailing significant progress across its business units, with several nearing profitability. Its Renergen subsidiary is set to commence helium production by Q3 2026, with annualized revenues projected at $27 million after Phase 1 completion and over $360 million after Phase 2. Renergen's holding company, Noble Africa, is also expected to become Nasdaq-listed via a reverse merger with ENDRA, with ASP Isotopes initially owning 89%. Other highlights include PET Labs' over 50% revenue growth in 1H 2026, forecasted $14 million FY2026 revenues, and the imminent commercial production of Silicon-28 and Ytterbium-176. The company also plans a public listing for its nuclear fuels subsidiary, Quantum Leap Energy, and is advancing its biotechnology unit, Alpa Theranostics, towards clinical trials.
Key Highlights
- Renergen to commence helium production by September 30, 2026.
- Renergen's Phase 1 annualized revenues projected at $27 million for helium and LNG.
- Renergen's Phase 2 projected annual revenues exceed $360 million at nameplate capacity.
- Noble Africa (Renergen's holding company) to list on Nasdaq via reverse merger with ENDRA.
- ASP Isotopes to initially own approximately 89% of the combined Noble Africa entity.
- PET Labs achieved over 50% organic revenue growth in 1H 2026 vs 1H 2025.
- PET Labs forecasts FY 2026 revenues of approximately $14 million, up from $6 million in 2025.
- Silicon-28 and Ytterbium-176 enrichment facilities expect initial product shipment in 2H 2026.
Price Impact
More from ASPI